Lower blood pressure goal in heart-attack shock patients
Part of Heart & circulation clinical trials.
This study compares two blood pressure targets in people with cardiogenic shock after a heart attack. It looks at whether the lower target can improve outcomes and help evaluate treatment costs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a recent heart attack (STEMI or NSTEMI)
- You received early heart treatment with a PCI procedure (a tube procedure to open blocked arteries)
- You have cardiogenic shock: your top blood pressure is low for over 30 minutes, or you need medicines to keep it above 90 at the time of randomization
- You show at least one sign that organs aren’t getting enough blood (like confusion, very cold/clammy skin, very low urine, or high lactate)
- You also have signs of fluid buildup in the lungs
- You were not shocked for more than 12 hours, and you did not need resuscitation for more than 30 minutes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a device called an intra-aortic balloon pump (a small balloon placed in your heart's main artery to help it pump) for people in the early stages of cardiogenic shock, a condition where the heart can't pump enough blood. The goal is to see if adding this supportive device early on improves outcomes for patients with heart attacks or other heart problems.
This trial tests whether setting a personalized blood pressure goal for each person in cardiogenic shock improves recovery compared to standard care. It may help if you have severe shock and can be enrolled within the first 24 hours.
This study looks at how people with cardiogenic shock (or very low blood pressure from heart causes) do after treatment in a specialized cardiovascular ICU. It also examines whether care by heart critical-care specialists affects outcomes.
This study compares two blood pressure support medicines (norepinephrine and dopamine) in adults with cardiogenic shock, a condition where the heart cannot pump enough blood. It aims to find which medicine works better for patients with this severe heart condition.
This study looks at whether adding two blood test markers (neutrophil-lymphocyte ratio and red cell distribution width) to a standard scoring system can better predict recovery or risk in patients with cardiogenic shock. If you are in the hospital with this condition, the results could help doctors understand your outlook more accurately.
This study tracks how well people with cardiogenic shock (a life-threatening drop in blood flow after a heart attack or heart failure worsening) do when treated with modern support devices and medicines.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.